(Boursier.com) — Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces today that it has received a Research Tax Credit in the amount of 1.8 million euros. euros.
This financial contribution will allow the company to extend its financial visibility until the end of September 2023, thus offering it more flexibility in its search for long-term financing and supporting its strategic ambitions.
“We remain convinced that the Prima System is a source of hope for patients suffering from dry AMD (geographic atrophy) and retinal diseases. This financial contribution strengthens the financial situation of Pixium, and will facilitate discussions with investors. It is becoming increasingly clear that in the future, patients with other profound central vision impairments will also be able to benefit from the Prima Bionic Vision System,” said Lloyd Diamond, Managing Director of Pixium Vision. “Following the recent granting of Breakthrough Device status by the FDA in March 2023, we are confident in the potential of photovoltaic neurostimulation to restore vision to patients with degenerative retinal diseases,” he added.
Pixium Vision is continuing its European pivotal study, which evaluates the safety and clinical benefits of the Prima System’s wireless micro-implant for patients with geographic atrophy due to age-related macular degeneration. At the end of 2022, the company carried out the 38 implantations necessary for the PRIMAvera study, the first data of which are expected towards the end of 2023 and marketing authorization in Europe in 2024.
Furthermore, Pixium Vision announces its participation in the Ophthalmology Tech Forum organized by Octane.
EXPERIENCE: Partnership Pursuit: Physician & Entrepreneur Reception (by invitation only)
Thursday, June 8, 4:30-5:30 p.m. – Salle Mariner
LUNCH & EXPERIENCE: Capital and Growth Main stage
Thursday, June 9, 1:15 p.m.-2:30 p.m. – Grand Ballroom
Facilitator: Andrew Douglas, Partner – Knobbe Martens
ROUNDTABLE: Bringing Unmet Needs to Market
Thursday June 9, 4-4:30 p.m. – Grand Ballroom
Moderator: Richard Lindstrom, MD – Minnesota Eye Consultants
Lloyd Diamond, Managing Director of Pixium Vision, will present in person.
In May 2023, Edison published an update to its investment research report, taking into account the announcement of Pixium’s 2022 annual report, the achievement of Breakthrough Device status in the United States and the conversion by ESGO which followed, valuing Pixium Vision at €140 million.